JOURNAL OF THE CZECH PHARMACEUTICAL SOCIETY AND THE SLOVAK PHARMACEUTICAL SOCIETY

Čes. slov. farm. 2008, 57(6):244-248

Consumption of hipolipidemics in the Czech Republic in 2000-2007

R. Bartas1,*, J. Kolář2
1 Lékárna Aqua, Karviná
2 Veterinární a farmaceutická univerzita Brno, Farmaceutická fakulta, Ústav aplikované farmacie

Hypolipidemics are a group of pharmaceuticals with an expressive portion on pharmaceuticals costs. Analysis of their consumption has been an object of repeated studies in our republic as well abroad. The present data on hypolipidemic drug utilization in 2000-2007 were obtained from the database of the State Institute of Drug Control. Utilization was expressed in defined daily doses (DDD) according to the ATC/DDD system, costs in Czech crowns. Utilization was expressed in relative values - DDD per 1 000 inhabitants per day (DID). The utilization of fibrates in the period under study is unchanged. The utilization of statins increased from 9.4 DID (2000) to 100 DID (2007). The maximal expenditures on hypolipidemic therapy were observed in 2005 (3 thousand million CZK). Statins are on the forefront of sales of medicines in the CR (2003-2006 - 1th place simvastatin, 2007 - 1th place atorvastatin (1th place in the world since 2001)).

Keywords: drug utilization; hypolipidaemics; statins; fibrates; ezetimibe

Received: September 15, 2008; Accepted: October 6, 2008; Published: June 1, 2008  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Bartas R, Kolář J. Consumption of hipolipidemics in the Czech Republic in 2000-2007. Čes. slov. farm. 2008;57(6):244-248.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Zdravotnická ročenka ČR 2006. Praha, ÚZIS ČR, 2007, 264 s.
    2. Zemřelí 2006. Praha, ÚZIS ČR, 2007, 104 s.
    3. Hospitalizovaní v nemocnicích ČR 2006., Praha, ÚZIS ČR, 2007, 150 s.
    4. Češka, R.: Remedia, 2006; 3, 261-267.
    5. Strnad, L., Práznovcová, L.: Zdravotnictví v České republice, 2001; 4, 151-154.
    6. Pavelková, R., Sobolová, L., Urbánek, K.: Klin. Farmakol. Farm., 2005; 19, 142-145.
    7. Prokeš, M.: Zdravotnictví a finance, 2007; 2, 3-14.
    8. Češka, R.: Kap. Kardiol., 2006; 8, 22-25.
    9. Bultas, J.: Zdravotnictví a finance, 2007; 2, 19.
    10. Walley, T., Folino-Gallo, P., Spephens, P., Van Ganse, E.: Br. J. Clin. Pharmacol., 2005; 60, 543-551. Go to original source... Go to PubMed...
    11. Chen, T., Lin, S., Chen, L. et al.: J. Chin. Med. Assoc., 2003; 66, 39-45.
    12. Sobolová, L.: Klin. Farmakol. Farm., 2005; 19, 22-26.
    13. Pfizer ukončil vývoj léku na cholesterol. [on line]., [cit. 2008-04-15]. Dostupný z www: <http://www.medical-tribune.cz/aktualita/1942>
    14. Štulc, T.: Lékařské listy, 2008; 10, 30-31.
    15. Bultas, J., Karetová, D.: Pace News, 2004; 3, 1-4.
    16. Teeling, M., Bennett, K., Feely, J.: Br. J. Clin. Pharmacol., 2004; 59, 227-232. Go to original source... Go to PubMed...
    17. First Head to Head Study Comparing Crestor and Lipitor Effects on the Treatment of Atherosclerosis. [on line]., [cit. 2008-06-05]. Dostupný z www: <http://www.medicalnewstoday.com/articles/94051.php>
    18. Lesná, M.: Zdravotnické noviny, 2008; 20, 14.
    19. Bultas, J.: Interní medicína, 2006; 7-8, 314-322.
    20. Kolář, J., Bartas, R.: Česká a slovenská farmacie, 2007; 56, 30-36.
    21. World Health Statistics 2008. World Health Organization 2008 [on line]., [cit. 2008-09-10]. Dostupný z www: <http://www.who.int/entity/whosis/whostat/EN_WHS08_Full.pdf>
    22. U.S. Patent and Trademark Office to Confirm Patentability of Lipitor Basic Patent. [on line]., [cit. 2008-08-17]. Dostupný z www: <http://findarticles.com/p/articles/mi_m0EIN/is_2008_April_30/ai_n25364225>
    23. Pfizer wins first round in Lipitor patent fight. [on line]., [cit. 2008-08-17]. Dostupný z www: <http://www.managingip.com/Article/1258148/Pfizer-wins-first-round-in-Lipitor-patent-fight.html>

    Return to the content


    Czech and Slovak Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.